KeyBank National Association
BLCM

KeyBank National Association’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

KeyBank National Association’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,662
Closed -$102K – 1064
2018
Q3 		$102K Sell
1,662
-207
-11% -$14K ﹤0.01% 1032
2018
Q2 		$138K Buy
1,869
+363
+24% +$28.3K ﹤0.01% 1010
2018
Q1 		$99K Buy
+1,506
New +$114K ﹤0.01% 1033

Other funds holding BLCM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KeyBank National Association's BLCM Position: Q4 2018 in Review

KeyBank National Association sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2018, closing a stake of 1,662 shares — an estimated $102K sold.

KeyBank National Association first reported a position in BLCM in Q1 2018 and held it in 3 quarters. The position peaked at $138K in Q2 2018. 92 funds tracked by Wall St. Rank hold BLCM as of Q4 2018.

  • KeyBank National Association reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • KeyBank National Association sold 1,662 Bellicum Pharmaceuticals, Inc. shares in Q4 2018, an estimated $102K.
  • KeyBank National Association first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2018 and held it in 3 quarters.
  • KeyBank National Association's Bellicum Pharmaceuticals, Inc. position peaked at $138K in Q2 2018.
  • 92 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2018.

Based on KeyBank National Association's 13F filing for Q4 2018, filed 30 Jan 2019.